William Deraedt
Overview
Explore the profile of William Deraedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
3183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhakal B, He J, Schecter J, Deraedt W, Slaughter A, Lonardi C, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966019
Background: Early continuous lenalidomide use for multiple myeloma (MM) treatment has led to more patients with lenalidomide-refractory disease at earlier lines of therapy (LOTs). Real-world treatment practices and outcomes in...
2.
Harrison S, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al.
N Engl J Med
. 2025 Feb;
392(7):677-685.
PMID: 39938094
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cilta-cel) in the phase 3 CARTITUDE-4 trial....
3.
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, et al.
Lancet Haematol
. 2025 Jan;
12(1):e45-e56.
PMID: 39756844
Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes....
4.
Yong K, Einsele H, Schecter J, Roccia T, Deraedt W, Lendvai N, et al.
Eur J Cancer
. 2024 Dec;
215:115157.
PMID: 39673835
Background: The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available...
5.
Dhakal B, Einsele H, Schecter J, Deraedt W, Lendvai N, Slaughter A, et al.
Blood Adv
. 2024 Aug;
8(19):5062-5071.
PMID: 39110988
In the context of multiple myeloma (MM), early use of the immunomodulatory drug lenalidomide has led to an increased population of patients with lenalidomide-refractory MM in early-line settings, but their...
6.
Htut M, Dhakal B, Cohen A, Martin T, Berdeja J, Usmani S, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
23(12):882-888.
PMID: 37716872
Background: Patients with prior allogeneic stem cell transplant (alloSCT) are typically excluded from trials of chimeric antigen receptor (CAR) T cell therapies, because their engineered cells may include allogeneic T...
7.
Delforge M, Vekemans M, Depaus J, Meuleman N, Velde A, Vande Broek I, et al.
Hemasphere
. 2022 Dec;
6(12):e813.
PMID: 36479545
No abstract available.
8.
Cohen A, Hari P, Htut M, Berdeja J, Usmani S, Madduri D, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):68-77.
PMID: 36357295
Introduction: Ciltacabtagene autoleucel (cilta-cel), a novel chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated early, deep, and durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM),...
9.
Martin T, Usmani S, Schecter J, Roccia T, Jackson C, Deraedt W, et al.
Curr Med Res Opin
. 2022 Oct;
39(1):81-89.
PMID: 36271807
Objective: This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of...
10.
Martin T, Lin Y, Agha M, Cohen A, Htut M, Stewart A, et al.
Lancet Haematol
. 2022 Oct;
9(12):e897-e905.
PMID: 36215989
Background: CARTITUDE-1 is a phase 1b-2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or...